News >

Dacomitinib Demonstrates Superior OS Versus Gefitinib in EGFR-Mutant NSCLC

Wayne Kuznar
Published: Wednesday, Jun 06, 2018

Tony Mok, MD

Tony Mok, MD

The investigational second-generation tyrosine kinase inhibitor (TKI) dacomitinib improved overall survival (OS) compared with gefitinib as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations. Median OS was 34.1 months in patients randomized to dacomitinib versus 26.8 months in those randomized to gefitinib (Iressa), according to the open-label, phase III ARCHER 1050 study presented at the 2018 ASCO Annual Meeting.1

With a median duration follow-up of 31.1 months, the data provide the first evidence of an OS advantage in a randomized direct comparison of 2 EGFR TKIs as first-line therapy for EGFR mutation-positive NSCLC.

Based on the finding, “dacomitinib should be considered as a new treatment option for first-line management of patients with EGFR mutation-positive advanced NSCLC,” said presenter Tony Mok, MD, professor and chair of the Department of Clinical Oncology, Chinese University of Hong Kong.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication